PHASE IV, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, CONTROLLED,60 DAYS, PARALLEL GROUPS, SUPERIORITY STUDY, TO COMPARE THE EFFECTIVENESS AND TOXICITY OF BEPOTASTINE 1.5% PF vs. OLOPATADINE 0.2% WITH BAK IN TREATMENT OF ALLERGIC CONJUNCTIVITIS

CompletadoFase 4ClinicalTrials.gov

ID: NCT04776096Tipo: INTERVENTIONALInicio: 10 de mar de 2021Fin estimado: 18 de ago de 2022

Traducción no disponible, mostrando original

Resumen

The present study will be carried out to evaluate the antiallergic efficacy of Bepotastine besilate 1.5% free of preservatives versus standard treatment with 0.2% Olopatadine hydrochloride with 0.1% benzalkonium chloride as preservative in adult patients diagnosed with allergic conjunctivitis. The antiallergic efficacy will be evaluated by the reduction of ocular signs and symptoms and by the resolution of non-ocular symptoms (rhinorrhea, congestion, and nasal pruritus), as well as the effect of the preservative and its relationship with the cytotoxicity of the ocular surface. Also will evaluate the safety of both products.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Patients older than 18 years old.
Clinical diagnosis of allergic conjunctivitis and active allergy with at least 2 points on itching and hyperemia scale.
Patients with history of allergic conjunctivitis.
Patients who accept no to wear contact lens during the duration of the trial.
Patients who accept no to use any other medication by any delivery route.
Patients with intraocular pressure controlled (less than 18 mmhg)

Criterios de exclusión

Patients who have undergone refractive surgery within the 6 months prior to the start of the study
Patient with ocular or systemic active diseases
Patients who are participating in another trial
Patients who have used eye medication in the last 15 days and/or who have received anti-inflammatory drugs (corticosteroids and/or NSAIDs) and/or antihistamines by mouth or intravenous.
Patients hypersensitive to any component of the products: Bepotastine besilate, sodium chloride, monosodium phosphate dihydrate, sodium hydroxide, Olopatadine hydrochloride, benzalkonium chloride, dibasic sodium phosphate, hydrochloric acid, edetate disodium or povidone K29 / 32.
Women who are breastfeeding and pregnant.

Intervenciones

drug

Olopatadine Hydrochloride 0.2% BAK

Olopatadine hydrochloride 0.2% with BAK as preservative

drug

Bepotastine Besilate 1.5% PF

Bepotastine besilate 1,5% Preservative free ophthalmic solution

Ubicaciones

Hospital de Alta Complejidad El Cruce - Nestor Kirchner

CABA, Argentina

Hospital Santa Lucía

CABA, Argentina

Instituto Oftalmológico Pedro Lagleyze

CABA, Argentina

Hospital Churruca - Visca

CABA, Argentina

Patrocinadores

PrincipalLaboratorios Poen

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

PHASE IV, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, CONTROL... | EligiMed